Rekombinanter CPA1 Antikörper (full length)
Kurzübersicht für Rekombinanter CPA1 Antikörper (full length) (ABIN7877797)
Target
Alle CPA1 Antikörper anzeigenAntikörpertyp
Reaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- full length
-
Verwendungszweck
- CPA1 Antibody / Carboxypeptidase A1
-
Aufreinigung
- Protein A/G affinity
-
Immunogen
- Recombinant full-length human CPA1 protein was used as the immunogen for the CPA1 antibody.
-
Isotyp
- IgG, kappa
-
-
-
-
Applikationshinweise
- Optimal dilution of the CPA1 antibody should be determined by the researcher.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 0.2 mg/mL
-
Buffer
- 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Aliquot the CPA1 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
-
-
- CPA1 (Carboxypeptidase A1 (Pancreatic) (CPA1))
-
Andere Bezeichnung
- CPA1
-
Hintergrund
- Human pancreatic procarboxypeptidase A exists as three different active forms, two of which are designated carboxypeptidase A1 (CPA1) and carboxypeptidase A2 (CPA2). CPA1, also known as CPA, is a 419 amino acid secreted monomeric protein that is highly expressed in pancreatic tissue. Functioning as a pancreatic exopeptidase, CPA1 uses zinc as a cofactor to catalyze the release of C-terminal amino acids from a variety of proteins, thereby playing a key role in protein digestion and degradation. Via its catalytic activity, CPA1 is also thought to be involved in zymogen (proenzyme) inhibition, probably functioning to block enzyme activation pathways. Abnormal levels of CPA1 are associated with pancreatic cancer, suggesting a possible role in either tumor progression or tumor suppression events.
-
UniProt
- P15085
Target
-